FeesSafety
Pluang+

DNO ASA's offer for Capricorn Energy plc lapses, ending the acquisition attempt.

Market News
09 Nov 2026, 14:00 WIB
Na
View Source
Neutral
DNO ASA's offer for Capricorn Energy plc lapses, ending the acquisition attempt.

DNO ASA announced that its offer to acquire Capricorn Energy plc has lapsed as of November 9, 2026. This means the acquisition attempt will not proceed, impacting DNO's expansion plans in the oil and gas sector. Investors should monitor DNO's next strategic moves following this development.

The lapse of the offer for Capricorn Energy plc provides context for energy sector investors. For readers following the Energy sector, here is Pluang's market snapshot as of Nov 09, 2026 14:11 WIB: out of 79 priced US energy stocks, 48 rose and 31 fell. Notable movers include Ecopetrol SA at USD 15.22 with a -4.40% change, Permian Resources Corporation Class A at USD 21.46 with a -4.32% change, and Valaris Limited at USD 79.77 with a -3.62% change.

More News

Oculis to host R&D Day showcasing late-stage pipeline for dry eye and neuro-ophthalmology treatments

Oculis to host R&D Day showcasing late-stage pipeline for dry eye and neuro-ophthalmology treatments

Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...

Market News
Bullish
13 minutes ago
Fraudulent robocall losses in North America to drop 33% by 2031 due to advanced fraud prevention.

Fraudulent robocall losses in North America to drop 33% by 2031 due to advanced fraud prevention.

Juniper Research forecasts that losses from fraudulent robocalls in North America will decrease by 33%, from $18.4 billion in 2026 to $12.3 billion in 2031. This decline is attributed to telecom operators adopting advanced fraud prevention technologi...

Market News
Bullish
13 minutes ago
Oculis announces R&D Day to showcase late-stage eye disease drug developments Licaminlimab and Privosegtor.

Oculis announces R&D Day to showcase late-stage eye disease drug developments Licaminlimab and Privosegtor.

Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...

Company Fundamentals
Bullish
13 minutes ago
OTC Markets appoints Olivier Roguez as VP to boost market data growth in EMEA.

OTC Markets appoints Olivier Roguez as VP to boost market data growth in EMEA.

OTC Markets Group named Olivier Roguez Vice President, Market Data for the EMEA region to lead business development and market data growth. Roguez brings over 20 years of experience from Cboe Global Markets and other firms, aiming to expand OTC Marke...

Market News
Bullish
5 hours ago
VAALCO Energy advances to second exploration phase at Côte d'Ivoire Block CI-705 after successful initial work.

VAALCO Energy advances to second exploration phase at Côte d'Ivoire Block CI-705 after successful initial work.

VAALCO Energy has completed the First Exploration Phase at Block CI-705 offshore Côte d'Ivoire and received government approval to proceed to the Second Exploration Phase. The block, where VAALCO holds a 70% interest, is located near existing oil fie...

Market News
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App